rss
Br J Ophthalmol 2001;85:91-92 doi:10.1136/bjo.85.1.91
  • Scientific correspondence

Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis

  1. Mark D Daniell1001,
  2. John K G Dart1002,
  3. Susan Lightman1002,1003
  1. 1001Corneal Service, Royal Victorian Eye and Ear Hospital, Melbourne, Australia, 1002Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK, 1003Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK
  1. John K G Dartjdart{at}dial.pipex.com
  • Accepted 5 July 2000

Abstract

AIMS To demonstrate that oral cyclosporin is successful in the management of steroid refractory post-keratoplasty atopic sclerokeratitis (PKAS).

METHODS Series of three patients.

RESULTS The patients developed PKAS between 2 and 11 days after surgery. All cases failed to respond to oral prednisolone 60–80 mg daily for 10–30 days but resolved with the addition of systemic cyclosporin 5.0–7.5 mg/kg/day. There have been no relapses following withdrawal of therapy after 3–18 months.

CONCLUSIONS PKAS is an uncommon, but severe, complication of corneal graft surgery and often responds to oral prednisolone treatment. Oral cyclosporin results in rapid resolution of PKAS in steroid unresponsive cases.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Register for free content


    Free sample
     This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.